Flotation

UW Madison’s small-molecule therapy spinout has raised $170m in venture funding since emerging from stealth less than a year ago.

Hyundai, Kia and GV are contributing to a $350 PIPE in support of a reverse merger that will value the Maryland and Duke-linked company at $2bn.

University of Pennyslvania and Caltech are in line for exits when Stanford’s online education spinout lists on the New York Stock Exchange.

Immuno-oncology therapy developer Lava Therapeutics has filed for a $100m IPO, having been set up in 2016 to exploit Amsterdam University Medical Centers research.

Caltech spinout Talis Biomedical has raised more than $220m in an initial public offering on the Nasdaq Global Market.

NexImmune priced shares at $17 to raise $110m in an upsized offering, enabling Amgen and Pfizer to exit the Johns Hopkins University spinout.

Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.

Nucana, a Scottish Investment Bank-backed cancer treatment developer, and Nightstar Therapeutics, an Oxford spinout focused on retinal gene therapies, have entered the public market.